WuXi Biologics CDMO
Provider 
Founded 2014
Sells To Enterprise
Pricing Model Recurring
Ownership Public
WuXi Biologics CDMO
Service
CDMO service for discovery, development, and cGMP manufacture of biologics.
- Currently Offered
CDMO service for discovery, development, and cGMP manufacture of biologics.
WuXi Biologics CDMO is the biologics contract development and manufacturing offering of WuXi Biologics, a global CRDMO. Its expertise spans discovery, development, and cGMP manufacture of biologics from mammalian cell culture.
The service provides pharmaceutical and biotechnology customers an integrated platform for advancing biologic programs. Work spans antibody generation and engineering through development and cGMP manufacturing using mammalian cell culture.
| Attribute | WuXi Biologics CDMO | Bionovis Biotec | Biotec | |
|---|---|---|---|---|
| Provider | |  |  | |
| Founded | 2014 | 2012 | 1958 | |
| Sells To | Enterprise | — | Consumers, Enterprise | |
| Pricing Model | Recurring | — | Recurring, Software | |
| Ownership | Public | — | Private |
Provider
Founded 2014
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider
Founded 1958
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Private
AbbVie contract manufacturing service producing monoclonal antibody biologics.
BioXcellence is Boehringer Ingelheim's biopharmaceutical contract manufacturing service.
Catalent's CDMO services span end-to-end development and manufacturing for pharma, biotech and self-care companies.
Integrated biologics development from lead stage to regulatory submission targeting about 30 percent time savings.
AbbVie contract manufacturing service producing monoclonal antibody biologics.
BioXcellence is Boehringer Ingelheim's biopharmaceutical contract manufacturing service.
Catalent's CDMO services span end-to-end development and manufacturing for pharma, biotech and self-care companies.
Integrated biologics development from lead stage to regulatory submission targeting about 30 percent time savings.